AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9635652
Drug: Air insufflation
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air insufflation technique (500 mL of air instilled into the stomach)
Trial: 8171951
Drug: Fentanyl (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (0.1 mg prior to surgery, 0.05 mg every 30 min during surgery)
Trial: 8171951
Drug: Alfentanil (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil (0.5 mg prior to surgery, 0.25 mg every 15 min during surgery)
Trial: 3335192
Drug: Kreon, three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kreon, three times six capsules daily
Trial: 3335192
Drug: Panzytrat 20.000,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panzytrat 20.000, three times three capsules daily
Trial: 30633580
Drug: Oral Nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Nutritional Supplements (ONS)
Trial: 29789878
Drug: Full-dose nut
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose nut diet (75 g/day mixed nuts)
Trial: 29789878
Drug: Full-dose muffin
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose muffin diet (three whole-wheat muffins, 188 g/day)
Trial: 29789878
Drug: Half-dose nut
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose nut diet (half portions of both nuts and muffins)
Trial: 29789878
Drug: Full-dose nut
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose nut diet
Trial: 27389118
Drug: Ultrasound-guided genicular
RxNorm normalized name: Sus scrofa thalamus lateral geniculate nucleus preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided genicular nerve pulsed RF treatment
Trial: 21417811
Drug: Ozone therapy
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone therapy (major autohemotherapy, minor autohemotherapy, and rectal ozone insufflation)
Trial: 21417811
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (silymarin and/or multivitamins)
Trial: 14599834
Drug: Percutaneous release
RxNorm normalized name: PERCUTANEOUS INTRODUCER SET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous release with steroid injection
Trial: 30915366
Drug: Steroid injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid injection alone
Trial: 7829015
Drug: Cyclical antibiotics
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclical antibiotics (ampicillin, metronidazole, ciprofloxacin) and ursodeoxycholic acid
Trial: 7829015
Drug: Cyclical antibiotics
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclical antibiotics and ursodeoxycholic acid
Trial: 29141460
Drug: Metformin up-titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin up-titration (1,500-2,250 mg/day)
Trial: 29141460
Drug: Control (maintaining
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (maintaining low-dose metformin)
Trial: 29141460
Drug: Metformin up-titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin up-titration
Trial: 26515419
Drug: Extended-release niacin
RxNorm normalized name: niacin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release niacin (ERN; 1-2 g/d)
Trial: 20184222
Drug: Fluoxetine (reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (reference formulation)
Trial: 18383987
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (diet with > 30 g of fiber and < 16 g of saturated fat, exercise 5-6 days/week, strength training 3 days/week, stress management 10-20 minutes daily)
Trial: 16723101
Drug: Isosorbide mononitrate
RxNorm normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide mononitrate (IMN) 40 mg with dinoprostone 3 mg
Trial: 16723101
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with dinoprostone 3 mg
Trial: 10921762
Drug: Salbutamol via
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol via Diskus (cumulative doses of 200, 400, 800, 1600, and 3200 microg)
Trial: 10921762
Drug: Salbutamol via
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol via Turbuhaler (cumulative doses of 200, 400, 800, 1600, and 3200 microg)
Trial: 8833682
Drug: Antidepressant-treated group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant-treated group
Trial: 8833682
Drug: Referent group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Referent group without antidepressant treatment
Trial: 1452374
Drug: Diltiazem (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (30 mg three times a day)
Trial: 6483162
Drug: Doxefazepam 10
RxNorm normalized name: doxefazepam
DrugBank: Doxefazepam (DB13837)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxefazepam 10 mg
Trial: 6483162
Drug: Doxefazepam 20
RxNorm normalized name: doxefazepam
DrugBank: Doxefazepam (DB13837)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxefazepam 20 mg
Trial: 6483162
Drug: Doxefazepam 40
RxNorm normalized name: doxefazepam
DrugBank: Doxefazepam (DB13837)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxefazepam 40 mg
Trial: 6483162
Drug: Doxefazepam 10
RxNorm normalized name: doxefazepam
DrugBank: Doxefazepam (DB13837)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxefazepam 10 mg (2-week administration)
Trial: 6483162
Drug: Doxefazepam 10
RxNorm normalized name: doxefazepam
DrugBank: Doxefazepam (DB13837)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxefazepam 10 mg (self-administered at home)
Trial: 25213640
Drug: Pain induced
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain induced by injection of hypertonic saline into vastus medialis (VM)
Trial: 25213640
Drug: Pain induced
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain induced by injection of hypertonic saline into rectus femoris (RF)
Trial: 12169127
Drug: Aminoglycoside and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminoglycoside and steroid preparation
Trial: 12169127
Drug: Steroid preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid preparation without aminoglycoside
Trial: 10451909
Drug: Intranasal GHRH
RxNorm normalized name: GHRH(1-44)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal GHRH (300 micrograms)
Trial: 8963361
Drug: Low fat/high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low fat/high fiber diet (25.5 energy‐% fat, 58.5 energy‐% carbohydrate, 3.9 g dietary fiber/MJ)
Trial: 1978471
Drug: Remoxipride twice
RxNorm normalized name: remoxipride
DrugBank: Remoxipride (DB00409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remoxipride twice daily
Trial: 1978471
Drug: Remoxipride three
RxNorm normalized name: remoxipride
DrugBank: Remoxipride (DB00409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remoxipride three times daily
Trial: 1978471
Drug: Haloperidol three
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol three times daily
Trial: 111119
Drug: Cefoxitin, 2
RxNorm normalized name: CefOXitin, 2 g injectable powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin, 2 g, intramuscularly
Trial: 111119
Drug: Procaine penicillin
RxNorm normalized name: procaine penicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procaine penicillin G, 4.8 million U, intramuscularly
Trial: 31338640
Drug: Topical lotion
RxNorm normalized name: Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lotion CG428, applied twice per day for 6 months
Trial: 31338640
Drug: Placebo, applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, applied twice per day for 6 months
Trial: 15232329
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 to 40 mg/d)
Trial: 15232329
Drug: Imipramine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (75 to 200 mg/d)
Trial: 9241284
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g of elemental calcium for 6 weeks
Trial: 8231904
Drug: 17 beta‐oestradiol-releasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 beta‐oestradiol-releasing vaginal ring (53 mg)
Trial: 3619421
Drug: 50 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/kg mezlocillin
Trial: 3619421
Drug: 80 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/kg mezlocillin
Trial: 22095545
Drug: Fosfomycin/tobramycin for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosfomycin/tobramycin for inhalation (FTI) 160/40 mg
Trial: 22095545
Drug: Fosfomycin/tobramycin for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosfomycin/tobramycin for inhalation (FTI) 80/20 mg
Trial: 1554660
Drug: PGE2 gel
RxNorm normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PGE2 gel (2 mg) instilled into the posterior fornix, with a further dose of 1 mg if contractions did not commence after 6 hours
Trial: 27136412
Drug: High-dose aerobic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose aerobic exercise
Trial: 23945965
Drug: Nifedipine controlled-release
RxNorm normalized name: nifedipine Extended Release Oral Tablet [Afeditab CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine controlled-release 40 mg b.i.d.
Trial: 23945965
Drug: Nifedipine controlled-release
RxNorm normalized name: nifedipine Extended Release Oral Tablet [Afeditab CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine controlled-release 40 mg q.d.
Trial: 19250152
Drug: Online cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online cognitive behavioural therapy (CBT)
Trial: 20487589
Drug: 48 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 48 g/d WG cereal (WGM)
Trial: 20487589
Drug: 48 g
RxNorm normalized name: GLYCERIN 3 g in 48 g CUTANEOUS OINTMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 48 g placebo cereal (non‐whole grain (NWG))
Trial: 15692967
Drug: Oral cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclophosphamide for treatment of SSc-associated interstitial lung disease
Trial: 11965271
Drug: Nicorandil 20
RxNorm normalized name: nicorandil 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil 20 mg twice daily
Trial: 7734095
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 mg twice daily for 1 week)
Trial: 7009264
Drug: Mixed meals
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed meals (20, 40, and 60 g of complex carbohydrate)
Trial: 7009264
Drug: Dextrose (20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose (20, 40, and 60 g)
Trial: 28955715
Drug: siponimod 2
RxNorm normalized name: siponimod 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: siponimod 2 mg once daily (preceding treatment)
Trial: 28955715
Drug: siponimod 2
RxNorm normalized name: siponimod 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: siponimod 2 mg once daily (interrupted treatment)
Trial: 28955715
Drug: siponimod 2
RxNorm normalized name: siponimod 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: siponimod 2 mg once daily (concomitant treatment)
Trial: 28955715
Drug: siponimod 2
RxNorm normalized name: siponimod 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: siponimod 2 mg once daily (all groups)
Trial: 21069381
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBOT) at 2.0 atm with inhalation of 100% oxygen for 60 min at 3, 24, and/or 48 hours after hepatectomy.
Trial: 16897112
Drug: Stanger bath
RxNorm normalized name: Stangard
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stanger bath therapy combined with amitriptyline (10 mg/day for 8 weeks)
Trial: 16897112
Drug: Amitriptyline (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (10 mg/day for 8 weeks) alone
Trial: 14962012
Drug: Theophylline 7
RxNorm normalized name: theophylline 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline 7 mg kg‐1
Trial: 11274240
Drug: High-dose omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose omega-3 fatty acids (EPA 3.76 g and DHA 2.94 g daily)
Trial: 11274240
Drug: Low-dose omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose omega-3 fatty acids (EPA 1.88 g and DHA 1.47 g daily)
Trial: 9674329
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil suspension, 15 mg/kg, single oral dose
Trial: 5171687
Drug: Expressed human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Expressed human milk and proprietary breast-milk substitute (S26) with protein intake of not more than 4.5 g/kg/day
Trial: 5171687
Drug: Evaporated milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaporated milk formula with protein intake ranging from 6.15 to 12.3 g/kg/day
Trial: 31672458
Drug: Sevelamer (1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevelamer (1600 mg three times daily)
Trial: 28768531
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Glycopyrronium + Indacaterol)
Trial: 25511789
Drug: Levetiracetam (LEV),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (LEV), 500 mg/body every 12 hours until postoperative day 7
Trial: 25511789
Drug: Phenytoin (PHT),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenytoin (PHT), 15-18 mg/kg fosphenytoin followed by 125 mg PHT every 12 hours until postoperative day 7
Trial: 23332040
Drug: Biofortified cassava
RxNorm normalized name: cassava
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofortified cassava porridge with added oil (2 mg β-carotene, 15 ml peanut or rapeseed oil, 20 g total fat)
Trial: 23332040
Drug: Biofortified cassava
RxNorm normalized name: cassava
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofortified cassava porridge without added oil (2 mg β-carotene, 6 g total fat)
Trial: 23332040
Drug: Unfortified white
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unfortified white cassava porridge with added oil (0.3 mg retinyl palmitate, 20 g total fat)
Trial: 8849179
Drug: Pefloxacin 400
RxNorm normalized name: pefloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pefloxacin 400 mg
Trial: 30341109
Drug: Arrabidaea chica
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arrabidaea chica herbal gel (2.5% standardised extract)
Trial: 28934783
Drug: Vertebral augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vertebral augmentation using a polyetheretherketone implant
Trial: 26312480
Drug: DPP treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPP treatments (specific treatments not detailed)
Trial: 20828943
Drug: Disulfiram 62.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disulfiram 62.5 mg/day
Trial: 20828943
Drug: Disulfiram 125
RxNorm normalized name: disulfiram 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disulfiram 125 mg/day
Trial: 10467834
Drug: C-reactive protein
RxNorm normalized name: C-reactive protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-reactive protein (CRP) estimation during treatment
Trial: 7883114
Drug: T-cell reactivity
RxNorm normalized name: Virus Specific T-Cell
DrugBank: Virus Specific T-Cell (DB15735)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-cell reactivity to beta-cell membrane preparation enriched for insulin-secretory granule antigen in newly diagnosed IDDM patients
Trial: 7883114
Drug: T-cell reactivity
RxNorm normalized name: Virus Specific T-Cell
DrugBank: Virus Specific T-Cell (DB15735)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-cell reactivity in children in remission for insulin dependency (honeymoon period)
Trial: 385093
Drug: Progesterone 200
RxNorm normalized name: progesterone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone 200 mg b.d.
Trial: 385093
Drug: Progesterone 400
RxNorm normalized name: progesterone 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone 400 mg b.d.
Trial: 23967738
Drug: ADV (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADV (10 mg/day, orally) plus peg‐IFN (180 microg/week, subcutaneous injection) for 48 weeks
Trial: 23967738
Drug: ADV plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADV plus LAM (100 mg/day, orally) for 48 weeks followed by continued LAM treatment for an additional 24 weeks
Trial: 22086229
Drug: Intravesical gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical gemcitabine 2,000 mg once per week for 6 weeks
Trial: 11575342
Drug: Amrinone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amrinone (5 microg kg(‐1) min(‐1) after a loading dose of 1.0 mg kg(‐1))
Trial: 7889898
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (2.4 g n‐3 fatty acids)
Trial: 29752345
Drug: Dual-hormone closed-loop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-hormone closed-loop system
Trial: 29752345
Drug: Single-hormone closed-loop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-hormone closed-loop system
Trial: 22910287
Drug: ID3 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ID3 (3 μg HA per strain)
Trial: 22910287
Drug: ID9 (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ID9 (9 μg HA per strain)
Trial: 22910287
Drug: INT9 (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INT9 (9 μg HA per strain)
Trial: 22910287
Drug: IM15 (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM15 (15 μg HA per strain)
Trial: 10640975
Drug: Neoadjuvant androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant androgen deprivation therapy (ADT) for 3 months followed by radical prostatectomy (RP)
Trial: 3330031
Drug: Nitrendipine (5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (5-20 mg b.d.)
Trial: 3330031
Drug: Propranolol (40-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40-120 mg b.d.)
Trial: 29705484
Drug: Cold therapy
RxNorm normalized name: Deep Cold Therapy
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold therapy (ice packs for 20 minutes prior to chest tube removal)
Trial: 29705484
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (listening to music for 30 minutes starting 15 minutes prior to chest tube removal)
Trial: 29705484
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cold and music therapy
Trial: 11195032
Drug: Isotonic sodium
RxNorm normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic sodium chloride solution
Trial: 21189767
Drug: Gantrez‐NNP combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gantrez‐NNP combination
Trial: 18729245
Drug: 500 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/day EFLA943 for 8 weeks
Trial: 18729245
Drug: 1000 mg/day
RxNorm normalized name: RibaTab 1000 MG/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg/day EFLA943 for 8 weeks
Trial: 18729245
Drug: Low-dose group
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose group (500 mg/day EFLA943)
Trial: 18729245
Drug: High-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose group (1000 mg/day EFLA943)
Trial: 10340912
Drug: SB 209670
RxNorm normalized name: SB 224289
DrugBank: SB 224289 (DB17052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB 209670 infusion at doses ranging from 0.2 to 1.5 microg kg(‐1) min(‐1) for approximately 8 hours
Trial: 7582196
Drug: Cilazapril 2
RxNorm normalized name: cilazapril 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril 2 mg daily, starting 7 days before PTCA and continuing for 6 months
Trial: 28523795
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health literacy intervention (5 sessions, 1.5 hours each over 1 year)
Trial: 28523795
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health literacy intervention
Trial: 9241623
Drug: Enalapril (2.5‐5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (2.5‐5 mg daily)
Trial: 3430295
Drug: Griseofulvin 1
RxNorm normalized name: griseofulvin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Griseofulvin 1 g daily